Join
Live feed
·
PRReleasevia Quantisnow
Verona Pharma plc logo

Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD

ByQuantisnow·Wall Street's wire, on your screen.
VRNA· Verona Pharma plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VRNA (Verona Pharma plc) and more on Quantisnow.